Structural Diversity Problems and the Solving Method for Antibody Light Chains

The structural diversity (heterogeneity) problem of antibodies has become a big subject along with the development of antibody drugs and catalytic antibodies. The detailed studies on the subject have not been conducted because many difficult and complex problems are existed in the phenomena. The heterogeneity problem is observed in a whole antibody as well as a catalytic antibody. The difficulty and complexity of the heterogeneity are in the generation of many isoforms caused by different charges, different molecular sizes, and/or modifications of amino acid residues. We found that the constant region domain of the antibody light chain also plays an important role in the heterogeneity. It is desirable that the antibody and/or the subunits must have a defined structure for practical use. We found interesting phenomena that copper ion can convert the multi-molecular forms of antibodies to mono-molecular forms. The ion contributed greatly to the enrichment of the dimer-form and the homogenation of the differently charged full-length and constant region domain of the light chain. The role of copper ion must be significant for preparing a single, defined, not multiple, isoform structure. Note that the big problem could be solved by using copper ion during the purification process.

[1]  R. Kato,et al.  Role of the constant region domain in the structural diversity of human antibody light chains , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  M. Guerreiro,et al.  Trastuzumab in the Treatment of Breast Cancer , 2016, BioDrugs.

[3]  S. Matsumoto,et al.  A novel method of preparing the monoform structure of catalytic antibody light chain , 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  S. Matsumoto,et al.  Biochemical features and antiviral activity of a monomeric catalytic antibody light‐chain 23D4 against influenza A virus , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  A. Pattanayak,et al.  Catalytic Immunoglobulin Gene Delivery in a Mouse Model of Alzheimer’s Disease: Prophylactic and Therapeutic Applications , 2015, Molecular Neurobiology.

[6]  Y. Nishiyama,et al.  Metal-dependent amyloid β-degrading catalytic antibody construct. , 2014, Journal of biotechnology.

[7]  C. Noe,et al.  Quality Control and Stability Studies with the Monoclonal Antibody, Trastuzumab: Application of 1D- vs. 2D-Gel Electrophoresis , 2014, International journal of molecular sciences.

[8]  S. Matsumoto,et al.  Biochemical Features of a Catalytic Antibody Light Chain, 22F6, Prepared from Human Lymphocytes* , 2013, The Journal of Biological Chemistry.

[9]  A. Nishizono,et al.  Highly efficient method of preparing human catalytic antibody light chains and their biological characteristics , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  C. Noe,et al.  Comparison of two-dimensional gel electrophoresis patterns and MALDI-TOF MS analysis of therapeutic recombinant monoclonal antibodies trastuzumab and rituximab. , 2011, Journal of pharmaceutical and biomedical analysis.

[11]  V. Buneva,et al.  Affinity and catalytic heterogeneity and metal‐dependence of polyclonal myelin basic protein‐hydrolyzing IgGs from sera of patients with systemic lupus erythematosus , 2011, Journal of molecular recognition : JMR.

[12]  Nikita Kuznetsov,et al.  Reactibodies generated by kinetic selection couple chemical reactivity with favorable protein dynamics , 2011, Proceedings of the National Academy of Sciences.

[13]  M. Sawyer,et al.  Critical appraisal of trastuzumab in treatment of advanced stomach cancer , 2011, Cancer management and research.

[14]  K. Higashi,et al.  Catalytic digestion of human tumor necrosis factor‐α by antibody heavy chain , 2010, The FEBS journal.

[15]  Naoko Fujimoto,et al.  Characteristic features of InfA-15 monoclonal antibody recognizing H1, H3, and H5 subtypes of hemagglutinin of influenza virus A type. , 2010, Journal of bioscience and bioengineering.

[16]  V. Buneva,et al.  DNA-hydrolyzing activity of IgG antibodies from the sera of patients with tick-borne encephalitis. , 2010, Biochimie.

[17]  O. M. Durova,et al.  Strategies for induction of catalytic antibodies toward HIV-1 glycoprotein gp120 in autoimmune prone mice. , 2009, Molecular immunology.

[18]  S. Kaveri,et al.  Factor VIII‐hydrolyzing IgG in acquired and congenital hemophilia , 2009, FEBS letters.

[19]  Yasuhiro Nishiyama,et al.  Catalytic antibodies to HIV: physiological role and potential clinical utility. , 2008, Autoimmunity reviews.

[20]  A. Nishizono,et al.  Catalytic Features and Eradication Ability of Antibody Light-chain UA15-L against Helicobacter pylori* , 2008, Journal of Biological Chemistry.

[21]  C. Slaughter,et al.  Crystal structure of a glycosylated Fab from an IgM cryoglobulin with properties of a natural proteolytic antibody. , 2006, The Biochemical journal.

[22]  O. Favorova,et al.  Amylolytic activity of IgM and IgG antibodies from patients with multiple sclerosis. , 2003, Immunology letters.

[23]  T. Uda,et al.  Targeted destruction of the HIV-1 coat protein gp41 by a catalytic antibody light chain. , 2002, Journal of immunological methods.

[24]  N. Jaffrezic‐Renault,et al.  Investigating antibody-antigen binding with atomic force microscopy , 2002 .

[25]  B. Kabakoff,et al.  Identification of multiple sources of charge heterogeneity in a recombinant antibody. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[26]  S. Kaveri,et al.  Catalytic activity of antibodies against factor VIII in patients with hemophilia A , 1999, Nature Medicine.

[27]  A. Vlassov,et al.  Catalytic DNA-and RNA-hydrolyzing antibodies from milk of healthy human mothers , 1998, Applied biochemistry and biotechnology.

[28]  K. Yoshida,et al.  DNA-hydrolyzing activity of Bence Jones proteins. , 1998, Biochemical and biophysical research communications.

[29]  A. Chen,et al.  Capillary isoelectric focusing and sodium dodecyl sulfate-capillary gel electrophoresis of recombinant humanized monoclonal antibody HER2. , 1996, Journal of chromatography. A.

[30]  R. Radulescu Antibody constant region: potential to bind metal and nucleic acid. , 1995, Medical hypotheses.

[31]  C. Chang,et al.  Dual conformations of an immunoglobulin light-chain dimer: heterogeneity of antigen specificity and idiotope profile may result from multiple variable-domain interaction mechanisms. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[32]  E. Odintsova,et al.  Metal dependent hydrolysis of β‐casein by sIgA antibodies from human milk , 2011, Journal of molecular recognition : JMR.

[33]  M. Glassy,et al.  Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab. , 2009, Human antibodies.

[34]  A. Edmundson,et al.  Naturally Occurring Proteolytic Antibodies SELECTIVE IMMUNOGLOBULIN M-CATALYZED HYDROLYSIS OF HIV gp120* , 2004 .